4536.T
SANTEN PHARMACEUTICAL CO.,LTD.
プライム · 医薬品 · 医薬品 · JP
JPY 1,871.00
+0.19%Year over year
Reported trailing growth
- Revenue
- -2.8%
- EBITDA
- —
- EBIT
- +2.0%
- EPS
- +10.1%
- Free cash flow
- -32.5%
- Operating cash flow
- -28.6%
Forward estimates
Based on analyst estimates
- Revenue
- +0.8%
- EBITDA
- —
- EPS
- -9.0%
Three-year CAGR
- Revenue
- +1.5%
- EBITDA
- +67.2%
- EBIT
- +11.4%
- Net income
- +18.4%
- EPS
- +25.3%
- Free cash flow
- +22.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026